HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Alphamab Co Ltd (9966.HK) - Some Points Worth the Attention

Alphamab Co Ltd Placement (9966.HK) - Has No Potential to Be a Biopharma; Just Remain as a Biotech

Pre-IPO Kelun Biotech (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Kelun Biotech - Debut Is the Peak, and Then It Wanes?

Keymed Biosciences (2162.HK) - The $1.2B Deal with AstraZeneca for ADC and the Logic Behind

Equity Bottom-Up

<ul>
<li>KN046’s commercialization prospects is limited if it doesn’t demonstrate better results than PD-1 in head-to-head trial. The value of KN046 still lies in its potential to treat PDAC not sqNSCLC.</li>
<li>KN026 is difficult to become a blockbuster variety. JSKN003 may not have good opportunity in front of DS-8201. Many investors are unhappy with Alphamab’s credibility and information disclosure quality.</li>
<li>Alphamab’s valuation is already at low level. However, considering the current pessimistic sentiment towards biotech in HKEX, investors are advised to remain cautious, and just short-term trade is recommended.</li>
</ul>


KN046’s commercialization prospects is limited if it doesn’t demonstrate better results than PD-1 in head-to-head trial. The value of KN046 still lies in its potential to treat PDAC not sqNSCLC.
KN026 is difficult to become a blockbuster variety. JSKN003 may not have good opportunity in front of DS-8201. Many investors are unhappy with Alphamab’s credibility and information disclosure quality.
Alphamab’s valuation is already at low level. However, considering the current pessimistic sentiment towards biotech in HKEX, investors are advised to remain cautious, and just short-term trade is recommended.


Alphamab Co Ltd (9966.HK) - Valuation Is Already Low, but Many Issues Hinder the Bullish View